Acadian Asset Management’s AbCellera Biologics ABCL Stock Holding History

Acadian Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.36M	Buy	+173,062	New	+$846K	﹤0.01%	1173
2026 Q1	–	Sell	-7,226	Closed	-$24K	–	1999
2025 Q4	$24K	Buy	+7,226	New	+$32.3K	﹤0.01%	1894
2025 Q1	–	Sell	-178,839	Closed	-$521K	–	1580
2024 Q4	$521K	Buy	178,839 +165,468	+1,238%	+$461K	﹤0.01%	1064
2024 Q3	$34K	Buy	+13,371	New	+$37K	﹤0.01%	1898
2023 Q2	–	Sell	-6,070	Closed	-$45K	–	1697
2023 Q1	$45K	Sell	6,070 -224,735	-97%	-$2.04M	﹤0.01%	1526
2022 Q4	$2.33M	Buy	230,805 +195,443	+553%	+$2.26M	0.01%	647
2022 Q3	$348K	Buy	35,362 +1,169	+3%	+$12.8K	﹤0.01%	1086
2022 Q2	$365K	Buy	34,193 +5,070	+17%	+$42.9K	﹤0.01%	1064
2022 Q1	$283K	Buy	+29,123	New	+$276K	﹤0.01%	1131

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Acadian Asset Management's ABCL Position: Q2 2026 in Review

Acadian Asset Management opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 173,062 shares worth $1.36M. The stake represents ﹤0.01% of the portfolio and ranks #1173 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in ABCL as recently as Q4 2025.

Acadian Asset Management first reported a position in ABCL in Q1 2022 and has held it in 9 quarters since. The position peaked at $2.33M in Q4 2022. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Acadian Asset Management held 173,062 shares of AbCellera Biologics worth $1.36M as of Q2 2026.
AbCellera Biologics was a new Acadian Asset Management position in Q2 2026.
AbCellera Biologics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1173 holding.
Acadian Asset Management first reported a position in AbCellera Biologics in Q1 2022 and has held it in 9 quarters since.
Acadian Asset Management's AbCellera Biologics position peaked at $2.33M in Q4 2022.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.